New findings from a Phase 3 multicenter, randomized head-to-head study comparing ustekinumab and Enbrel(R) (etanercept) for the treatment of moderate to severe psoriasis showed ustekinumab superior to Enbrel according to primary and major secondary efficacy endpoints.

Original post by Epinions Recent Content for Golf